138 related articles for article (PubMed ID: 19443940)
21. [Leflunomide as a second choice treatment in patients with rheumatoid arthritis].
Raczkiewicz-Papierska A; Dudek A; Bachta A; Tłustochowicz M; Zawadyl B; Sułek M
Pol Merkur Lekarski; 2007 Jun; 22(132):547-50. PubMed ID: 17874627
[TBL] [Abstract][Full Text] [Related]
22. Susceptibility for and clinical manifestations of rheumatoid arthritis are associated with polymorphisms of the TNF-alpha, IL-1beta, and IL-1Ra genes.
Cvetkovic JT; Wallberg-Jonsson S; Stegmayr B; Rantapaa-Dahlqvist S; Lefvert AK
J Rheumatol; 2002 Feb; 29(2):212-9. PubMed ID: 11838837
[TBL] [Abstract][Full Text] [Related]
23. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study.
Mladenovic V; Domljan Z; Rozman B; Jajic I; Mihajlovic D; Dordevic J; Popovic M; Dimitrijevic M; Zivkovic M; Campion G
Arthritis Rheum; 1995 Nov; 38(11):1595-603. PubMed ID: 7488280
[TBL] [Abstract][Full Text] [Related]
24. Clinical experience with leflunomide in rheumatoid arthritis. Leflunomide Investigators' Group.
Rozman B
J Rheumatol Suppl; 1998 Jul; 53():27-32. PubMed ID: 9666415
[TBL] [Abstract][Full Text] [Related]
25. [Experience in long-term therapy of active rheumatoid arthritis with leflunomide].
Chichasova NV; Igolkina EV; Brodetskaia KA; Imametdinova GR
Ter Arkh; 2005; 77(5):33-8. PubMed ID: 15989000
[TBL] [Abstract][Full Text] [Related]
26. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide.
Strangfeld A; Hierse F; Kekow J; von Hinueber U; Tony HP; Dockhorn R; Listing J; Zink A
Ann Rheum Dis; 2009 Dec; 68(12):1856-62. PubMed ID: 19126559
[TBL] [Abstract][Full Text] [Related]
27. Rheumatoid arthritis and genetic variations in cytokine genes: a population-based study in Kashmir Valley.
Shafia S; Dilafroze ; Sofi FA; Rasool R; Javeed S; Shah ZA
Immunol Invest; 2014; 43(4):349-59. PubMed ID: 24484294
[TBL] [Abstract][Full Text] [Related]
28. Is there a rationale to using leflunomide in early rheumatoid arthritis?
Dayer JM; Cutolo M
Clin Exp Rheumatol; 2005; 23(3):404-12. PubMed ID: 15971434
[TBL] [Abstract][Full Text] [Related]
29. Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor.
Marotte H; Arnaud B; Diasparra J; Zrioual S; Miossec P
Arthritis Rheum; 2008 May; 58(5):1258-63. PubMed ID: 18438841
[TBL] [Abstract][Full Text] [Related]
30. The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study.
Finckh A; Dehler S; Gabay C;
Ann Rheum Dis; 2009 Jan; 68(1):33-9. PubMed ID: 18230627
[TBL] [Abstract][Full Text] [Related]
31. Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia.
Liao TL; Chen YM; Liu HJ; Chen DY
BMJ Open; 2017 Jan; 7(1):e014032. PubMed ID: 28057661
[TBL] [Abstract][Full Text] [Related]
32. Quality of life and clinical outcomes in Polish patients with high activity rheumatoid arthritis treated with leflunomide (Arava®) in Therapeutic Program: A retrospective analysis of data from the PLUS study.
Tłustochowicz ME; Kisiel B; Tłustochowicz W
Adv Clin Exp Med; 2019 Nov; 28(11):1545-1553. PubMed ID: 31660707
[TBL] [Abstract][Full Text] [Related]
33. [Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis].
Botsios C; Sfriso P; Furlan A; Ostuni P; Biscaro M; Fiocco U; Todesco S; Punzi L
Reumatismo; 2007; 59(1):32-7. PubMed ID: 17435840
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis.
Weinblatt ME; Kremer JM; Coblyn JS; Maier AL; Helfgott SM; Morrell M; Byrne VM; Kaymakcian MV; Strand V
Arthritis Rheum; 1999 Jul; 42(7):1322-8. PubMed ID: 10403258
[TBL] [Abstract][Full Text] [Related]
35. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.
Herrmann ML; Schleyerbach R; Kirschbaum BJ
Immunopharmacology; 2000 May; 47(2-3):273-89. PubMed ID: 10878294
[TBL] [Abstract][Full Text] [Related]
36. [Therapeutic effect and impact on cytokine production by methotrexate in rheumatoid arthritis].
Sun XY; Su Y; Ren LM; Han L; Li ZG
Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Aug; 38(4):356-9. PubMed ID: 16892137
[TBL] [Abstract][Full Text] [Related]
37. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study.
Kalden JR; Schattenkirchner M; Sörensen H; Emery P; Deighton C; Rozman B; Breedveld F
Arthritis Rheum; 2003 Jun; 48(6):1513-20. PubMed ID: 12794818
[TBL] [Abstract][Full Text] [Related]
38. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.
Emery P; Breedveld FC; Lemmel EM; Kaltwasser JP; Dawes PT; Gömör B; Van Den Bosch F; Nordström D; Bjorneboe O; Dahl R; Horslev-Petersen K; Rodriguez De La Serna A; Molloy M; Tikly M; Oed C; Rosenburg R; Loew-Friedrich I
Rheumatology (Oxford); 2000 Jun; 39(6):655-65. PubMed ID: 10888712
[TBL] [Abstract][Full Text] [Related]
39. Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomized trials.
Golicki D; Newada M; Lis J; Pol K; Hermanowski T; Tłustochowicz M
Pol Arch Med Wewn; 2012; 122(1-2):22-32. PubMed ID: 22353705
[TBL] [Abstract][Full Text] [Related]
40. The effects of disease-modifying anti-rheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical trials database.
Scott DL; Strand V
Rheumatology (Oxford); 2002 Aug; 41(8):899-909. PubMed ID: 12154207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
